The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer.

ABSTRACT:

Background

Lung adenocarcinoma frequently presents with EGFR mutations, often progressing on EGFR tyrosine kinase inhibitors (TKIs) despite an initial response. Progression is frequently driven by additional genetic changes, including mutations in tumor suppressor genes (TSGs). Understanding the role of these concurrent TSG mutations can help elucidate resistance mechanisms and guide the development of more effective treatment approaches.

Materials and methods

We examined survival outcomes in 483 EGFR-mutant (mEGFR) patients from the GENIE BPC non-small-cell lung cancer (NSCLC) dataset. To understand the mutational landscape and clonal dynamics, whole exome sequencing (WES) was carried out on 48 tumor samples from 16 mEGFR patients at both baseline and post-relapse. A compre

SUBMITTER: Hait S 

PROVIDER: S-EPMC11937282 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature